Prerpints.org logo
Preprint
Article

Post-Conization HPV Vaccination and Its Impact on Viral Status: A Retrospective Cohort Study in Troms and Finnmark, 2022

Altmetrics

Downloads

123

Views

50

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

07 April 2024

Posted:

08 April 2024

You are already at the latest version

Alerts
Abstract
Human papillomavirus (HPV) is associated with cellular changes of the cervix leading to cancer, which highlights the importance of vaccination in preventing HPV infections and subsequent cellular changes. Women undergoing treatment (LEEP) for high-grade cervical intraepithelial neoplasia (CIN2+) remain at risk for recurrence. This study assesses the effect of post-conization HPV vaccination on the viral status of women six months post-conization, aiming to evaluate the vaccine's effectiveness in preventing recurrence of CIN2+. A retrospective cohort study was conducted among women in Troms and Finnmark who underwent conization in 2022. Using the SymPathy database and the national vaccination register (SYSVAK), we analyzed the vaccination status and HPV test results of women born before 1991, who had not received the HPV vaccine prior to conization. Out of 419 women undergoing conization, 243 met the inclusion criteria. A significant association was found between post-conization HPV vaccination and a negative HPV test at six months follow-up (ARR = 12.1%, P = 0.039). Post-conization HPV vaccination significantly reduced the risk of a positive HPV test at the first follow-up, suggesting its potential in preventing recurrence of high-grade cellular changes. The retrospective design and the insufficient control of confounding variables underscore the necessity for further studies to confirm these findings.
Keywords: 
Subject: Medicine and Pharmacology  -   Obstetrics and Gynaecology

1. Introduction

In Norway, the National Cervical Screening Program aims to prevent cervical cancer by early identification and treatment of high-grade cervical intraepithelial neoplasia (CIN2+) before they progress to malignancy and reduce the incidence and mortality of cervical cancer [1,2]. The program, managed by the National Cancer Registry of Norway, was established as a national initiative in 1995 and targets women aged 25 to 69.
Starting from July 2023, participants will undergo high-risk HPV testing every five years, where positive results are followed up with microscopic examination of the cervical smear [3,4]. This represents a shift from the prior triennial microscopic evaluations that contributed to the observed decline in cervical cancer mortality since the 1980s [2]. Notably, in Norway, more than half of cervical cancer cases arise in individuals that were non-compliant with the screening recommendations.
Persistent infection with HPV can cause cervical intraepithelial neoplasia (CIN) [5], also known as cervical dysplasia or precancerous abnormal cells, and more than 99% of cervical cancers are linked to HPV [6]. The conventional management of CIN2+ involves conization, specifically the loop electrosurgical excision procedure (LEEP), which removes the lesion that has potential to progress to cervical cancer [7]. A follow-up examination post-conization is scheduled approximately six months later and includes an HPV test to inform further treatment [8]. In 2022, 6393 women underwent conization in Norway with an average age of 39.6 years, and the median age was 36 years [9]. Conization poses risks, such as an elevated likelihood of preterm births [10,11], highlighting the relevance of fertility considerations in this patient group. Preventing recurrence of CIN2+ in treated women will result in the prevention of potential re-conizations or hysterectomies, reducing the impact on fertility.
The HPV vaccine was introduced to the Norwegian childhood vaccination program in 2009 for seventh-grade girls (born from 1997 onwards), and extended to boys of the same grade in 2018 (born from 2006 onwards) [12]. A catch-up program from 2016 to 2018 offered the vaccine to unvaccinated women born after 1990, which achieved vaccination with at least one dose in 59% of women born between 1991-1996 [13]. By 2022, vaccination coverage reached 93% among 16-year-old girls. This extensive vaccination effort has not only increased coverage among the youth, but also indirectly increased herd immunity against HPV.
There are two different HPV vaccines available in Norway: Cervarix, which is utilized in the national vaccination program and covers HPV types 16 and 18, and Gardasil 9, which in addition to HPV types 16 and 18 also covers types 31, 33, 45, 52, 58 and genital warts caused by types 6 and 11 [14]. Cervarix offers cross-protection against additional HPV types beyond 16 and 18. Despite their inability to treat existing infections, these vaccines effectively prevent new HPV infections. Cervarix and Gardasil 9 demonstrate over 90% and up to 100% efficacy, respectively, against the development of CIN2+ associated with the vaccine's covered HPV types [12].
Emerging research suggests the HPV vaccine has potential to prevent recurrence of high-grade cervical dysplasia post-conization [15,16,17,18], yet there is a lack of consensus or national guidelines endorsing post-treatment HPV vaccination for CIN2+ [19]. Consequently, the decision to recommend vaccination post-conization is left to individual gynecologists, which combined with out-of-pocket costs [14], leads to disparities in vaccine uptake among treated women.
This study aims to evaluate the impact of post-conization HPV vaccination on the HPV status at the first follow-up six months post-treatment. Considering the link between HPV infections and over 99% of cervical dysplasia and cancers [6,20], this study seeks to indirectly determine the vaccine's role in mitigating the recurrence risk of CIN2+ by analyzing a comparison of HPV status between vaccinated and unvaccinated women post-conization.

2. Materials and Methods

2.1. Study Design

This retrospective cohort study was performed at the University Hospital of North Norway (UNN), Tromsø. Inclusion criteria were women who underwent conization in Troms and Finnmark during the year 2022. Exclusion criteria included absence of post-conization HPV test, HPV vaccination prior to conization, and birth after the year 1990.
The primary outcome measure, to assess the HPV vaccine's impact, was HPV status at the initial follow-up six months after conization. Exclusion of women vaccinated prior to conization ensured the separation of the vaccine's effects pre- and post-procedure. Additionally, exclusion of women born after 1990 was due to their eligibility for free vaccination under the national childhood vaccination or catch-up programs, leading to higher vaccination rates in this cohort compared to those born before 1991.

2.2. Data Collection Methodology

In this study we utilized the SymPathy database, a comprehensive Laboratory Information System (LIS) employed by the Department of Clinical Pathology at the University Hospital of North Norway (UNN). SymPathy serves as the central repository for all cervical cytology, histology, and HPV test specimens from women in Troms and Finnmark counties, representing approximately 5% of Norway's total population. This database is essential for the systematic registration, analysis, and management of patient data, playing a crucial role in the region's cervical cancer prevention efforts. For our research, SymPathy was instrumental in identifying women born before 1991 who underwent conization during 2022. These patients' cervical tissue samples are meticulously recorded and evaluated by department pathologists, adhering to standard operational procedures. Conization, primarily executed via the loop electrosurgical excision procedure (LEEP), results in tissue specimens being cataloged with the NORPAT code T83701, denoting cervix cone topography.
The SymPathy database aggregates extensive data on each patient, including identification numbers, historical screening outcomes, therapeutic actions, and follow-up evaluations featuring cytology and HPV test results. By leveraging the NORPAT code, we could efficiently extract data relevant to individuals treated with conization, encompassing HPV test outcomes 6 months post-procedure. The UNN uses the Roche Cobas 4800 system for HPV testing, which performs individual assessments for HPV types 16 and 18 and a pooled analysis for twelve additional HPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). This meticulous approach to data collection via SymPathy underscores the depth and reliability of our study's dataset.

2.3. HPV Vaccination Status Assessment

To ascertain the HPV vaccination status post-conization, data was retrieved from the national vaccination registry (SYSVAK) through a meticulous manual search process using the patient identification numbers. Vaccination status was classified into three distinct groups: 1) Vaccinated prior to conization, 2) Vaccinated subsequent to conization, and 3) Unvaccinated individuals. Patients who received an HPV vaccine both before and after conization were accounted for in both vaccinated groups. No differentiation was made based on the vaccine variant; any recipient of at least one vaccine dose was considered vaccinated. The timing of post-conization vaccination was not explicitly analyzed relative to HPV-testing, but it is presumed that the majority were vaccinated before HPV-testing at the six-month follow-up.

2.4. Ensuring Data Privacy Integrity

In adherence to privacy regulations and ensuring patient confidentiality, data collection was exclusively conducted by principal investigator (SWS), a senior consultant in pathology at the Department of Clinical Pathology, UNN. The anonymization process entailed the elimination of identifiable personal information, including names and identification numbers, to comply with ethical standards. Consequently, only anonymized frequency tables were provided to the authors for detailed analysis and manuscript development.

2.5. Statistical Evaluation

The analytical process involved the utilization of SPSS software for data processing, with the study cohort consisting of females born before 1991 who were unvaccinated prior to conization and had available HPV test results from the follow-up approximately six months after the procedure. Based on defined inclusion criteria, frequency distribution tables were generated to illustrate the age-specific HPV status and vaccination status, alongside the correlation between post-conization HPV vaccination and subsequent HPV test outcomes. Statistical significance was established at P < 0.05, with the Number Needed to Vaccinate (NNV) for preventing a single positive HPV test and Absolute Risk Reduction (ARR) being calculated manually.

3. Results

In 2022, conization specimens from 419 women residing in Troms and Finnmark were processed by the Department of Clinical Pathology at the University Hospital of North Norway (UNN). A subset of these women, specifically 25, did not undergo an HPV test post-conization for reasons including subsequent hysterectomy, treatment for cervical cancer with radiochemotherapy, or absence of follow-up at the time of data collection. From the remaining 394 women who did have an HPV test, 141 born after 1990 were excluded from the study due to their eligibility for prior vaccination programs. An additional 10 women were excluded for having received the HPV vaccine before their conization, despite not being eligible for the initial childhood vaccination or catch-up programs. Consequently, a total of 243 women met the criteria for inclusion in the study (Figure 1).
The distribution of HPV status within the study population, segmented by age, is detailed in Table 1. Participants were categorized into age groups spanning 10 years, with the youngest group being 30-39 years and the oldest 70-79 years. Within each age group, women were divided into two categories based on their post-conization HPV test results: HPV+ for positive tests and HPV– for negative tests.
The distribution of women across age groups showed a concentration in the youngest category (n = 108), with a progressive decrease in the number of participants in each subsequent older age group. Specifically, the age groups of 60-69 and 70-79 years comprised 16 and 8 participants, respectively.
Approximately six months following conization, the average rate of HPV positivity among participants younger than 60 years was 26.9%. In contrast, in the oldest age cohorts, a higher prevalence of 75% HPV positivity was observed after conization. The disparity in HPV positivity rates between participants younger than 60 years and those aged 60 and above was statistically significant (P < 0.001, Fisher’s exact test, one-sided).
The analysis of vaccination coverage revealed that the highest rates were among the three youngest age groups. Specifically, the age groups 30-39 and 50-59 years demonstrated similar vaccination rates of 37.0% and 36.7%, respectively, whereas the 40-49 age group exhibited a vaccination rate of 27.4%. Notably, vaccination coverage was markedly lower in the oldest age groups, with 12.5% in the 60-69 age group and 0% in the 70-79 age group.
Table 2 outlines the categorization of participants based on whether they received the HPV vaccine post-conization (YES or NO) and their HPV test results approximately six months after the procedure (HPV+ or HPV–).
Out of the 243 participants included in this study, 77 had been vaccinated post-conization. This represents less than one-third of the sample. A considerable proportion, 77 out of 243 (31.7%), tested positive for HPV about six months post-conization. The incidence of HPV positivity was 23.4% in the vaccinated group compared to 35.5% in the unvaccinated group, resulting in an Absolute Risk Reduction (ARR) of 12.1 percentage points. The significance of the vaccination's effect was evaluated using a one-sided Fisher’s exact test, yielding a P-value of 0.039 that indicates a significant correlation between post-conization vaccination and a negative HPV test at the six-month follow-up. The Number Needed to Vaccinate (NNV) to prevent a single positive HPV test six months post-conization was calculated to be 8.22.

4. Discussion

Evidence from multiple studies indicates that post-conization HPV vaccination may play a preventative role in the recurrence of high-grade intraepithelial neoplasia (CIN2+) [16,17,18]. Our research identified a notable reduction in HPV positivity rates six months after conization, from 35.5% in the unvaccinated group to 23.4% in the vaccinated group. This translates to an absolute risk reduction (ARR) of 12.1 percentage points in the likelihood of testing positive for HPV among vaccinated individuals compared to their unvaccinated counterparts. This outcome not only underlines the vaccine's potential in reducing the likelihood of future CIN2+, but also its role in mitigating cancer risk due to HPV.
The disparity in conization rates across age demographics can likely be linked to the prevalence of CIN2+ within the population. Data from Norway in 2022 reveal a median conization age of 36 years, with a noteworthy observation that only 149 out of 6393 women who underwent conization were aged 70 or above [9]. This trend suggests a decrease in conization procedures with advancing age. Notably, our study found the highest HPV positivity rates post-conization among the eldest cohorts. A contributing factor might be the minimal vaccination coverage observed in these groups, with only 2 out of 24 (8.3%) women aged 60 or above receiving the HPV vaccine post-conization. An alternative explanation could be the diminished immune response and weaker immune system prevalent in older populations [21]. However, the small sample size warrants caution in drawing definitive conclusions regarding this observed difference.
Less than a third of the study population opted for vaccination post-conization. This phenomenon is potentially due to the lack of explicit national guidelines on post-conization HPV vaccination. While our analysis did not delve into how economic, educational, or other socio-economic factors might influence vaccination decisions, the high cost of the vaccine suggests such variables could impact vaccination rates. The significant correlation between HPV vaccination and a negative HPV test post-conization confirms the vaccine's efficacy in lowering positive HPV test occurrences following conization. Nonetheless, the study's brief follow-up time limits our ability to link HPV test outcomes to the incidence of diagnosed recurrences of CIN2+. Consequently, HPV status serves merely as an indirect indicator of the vaccine's effectiveness against CIN2+ recurrence. A comprehensive evaluation of the vaccine's long-term impact necessitates extended follow-up periods.
Chen et al.'s prospective cohort study, with a 2-year follow-up, investigated the vaccine's influence on CIN2+ recurrence [15]. The analysis, which included HPV testing at 6 months, 1 year, and 2 years, defined recurrence through histologically confirmed CIN2+. They found a recurrence rate of 10.6% in the unvaccinated group compared to 2.0% in the vaccinated group, demonstrating a significant reduction in CIN2+ recurrence among those who received the vaccine (P = 0.001). The severity of cervical dysplasia at conization and the HPV type detected prior to conization were considered as confounding factors. Although initial 6-month findings showed no significant difference in HPV positivity rates between vaccinated and unvaccinated groups, a substantial decrease in positive tests was noted in the vaccinated group at the 2-year mark (8.1% versus 15.8%, P = 0.026). This evidence suggests the vaccine's efficacy against HPV may increase over time, indicating the potential of observing a greater preventative effect in our study with a prolonged observation period.
Various studies, inclusive of meta-analyses and a randomized controlled trial (RCT), have substantiated the preventive efficacy of the HPV vaccine against the recurrence of CIN2+ [18,22,23]. Studies regarding the vaccine's potential protective effect post-conization frequently utilize histologically verified CIN2+ as an evaluative endpoint. Our investigation utilized the HPV test to assess the post-conization vaccine impact. According to Kreimer et al., a similar HPV test to the one used in this study exhibits a 99% negative predictive value for CIN2+ [24], suggesting that the increased proportion of women with a negative HPV test within the vaccinated cohort is a suitable indicator for diminished risk of post-conization recurrence of CIN2+. This corroborates the observed prophylactic vaccine benefit.
Nonetheless, our study has limitations, including a modest sample size and a skewed ratio of vaccinated to unvaccinated participants. Moreover, the study witnessed an uneven age distribution, coupled with a significant variance in HPV test results across the youngest and eldest age brackets, which established age as a confounding variable. The study's retrospective format diminished our capacity to adjust for other potential confounders due to the non-collection of data such as socio-economic status, sexual partnership history, smoking habits, or immunosuppressive conditions. The correlation between the severity of the cervical dysplasia and positive post-conization HPV tests were not explored, nor whether the entirety of the area with cervical dysplasia was excised during conization (ensuring clear resection margins).
The investigation did not meticulously analyze the timing of vaccination in relation to conization, potentially leading to imprecise classifications regarding vaccination status. While the assumption was that a majority were vaccinated before the initial HPV test six months post-conization, it is possible that a subset was vaccinated afterward. This could potentially cloud the accuracy assessment of the vaccine's true efficacy. Nonetheless, given the observed effect of the vaccine, it's reasonable to infer that most participants were likely vaccinated before their first post-conization HPV test. A more detailed examination of the vaccination timeline might have provided stronger support for the study's conclusions. The study did not detail the specific HPV vaccine types used or the number of doses administered prior to the HPV test, limiting the ability to evaluate whether vaccines against a broader-spectrum of HPV-types or a higher number of doses might lead to more negative HPV tests.

5. Conclusions

This study's findings indicate that administering the HPV vaccine after conization significantly increases the likelihood of a negative HPV test at the six-month follow-up. This emphasizes the vaccine's potential utility in diminishing the risk of recurrence for high-grade intraepithelial neoplasia (CIN2+) post-treatment, corroborating evidence presented in previous research. However, the limited sample size, short follow-up duration, and the study's retrospective nature, which restricted comprehensive evaluation of all potential confounding variables, highlight the necessity for further empirical inquiry to substantiate these preliminary observations. The call for additional research is particularly pressing in light of the absence of national guidelines for post-conization HPV vaccination, despite a growing evidence base that supports its implementation. The current scarcity of randomized controlled trials examining the vaccine's effect in this context underscores the critical need for ongoing and future studies to definitively establish the vaccine's impact on post-conization HPV status and recurrence of CIN2+.

Author Contributions

Conceptualization, S.W.S.; writing—original draft preparation, M.R., H.M.W., S.W.S. and E.R.; writing—review and editing, M.R., H.M.W., S.W.S. and E.R.; visualization, M.R. and H.M.W.; supervision, S.W.S. and E.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The follow-up protocol post-conization was appraised by the Regional Committee for Medical and Health Research Ethics (REK Nord) as a component of health service quality assurance (2015/2479/REK Nord).

Informed Consent Statement

According to Norwegian regulations, quality assurance projects are exempt from the requirement of obtaining written informed consent from participants.

Data Availability Statement

The raw data supporting the conclusions of this article will be made available by the authors on request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Cancer Registry of Norway. Cervical Cancer Screening Programme. (updated 22 February 2023). Available online: https://www.kreftregisteret.no/en/screening/cervix/org/ (accessed on 29 March 2024).
  2. Cancer Registry of Norway. Cervical Cancer. (updated 15 August 2023). Available online: https://www.kreftregisteret.no/en/Temasider/Cancers/Cervical-cancer/ (accessed on 4 February 2024).
  3. Cancer Registry of Norway. Innføring av HPV-test til yngre vil førebygge fleire krefttilfelle [Implementation of HPV testing to Younger Ages Will Prevent More Cancer Cases]. (updated 28 June 2023). Available online: https://www.kreftregisteret.no/Generelt/Nyheter/2023/innforing-av-hpv-test-til-yngre-vil-forebygge-fleire-krefttilfelle/ (accessed on 29 March 2024).
  4. Norwegian Cancer Society (NCS). Livmorhalsprøve (HPV-test og celleprøve fra livmorhalsen) [Cervical Smear (HPV test and Cervical Cytology)]. (updated 19 March 2024). Available online: https://kreftforeningen.no/om-kreft/undersokelser/livmorhalsprove-celleprove-av-livmorhalsen/ (accessed on 6 April 2024).
  5. Kjær, S.K.; Frederiksen, K.; Munk, C.; Iftner, T. Long-term Absolute Risk of Cervical Intraepithelial Neoplasia Grade 3 or Worse Following Human Papillomavirus Infection: Role of Persistence. JNCI: Journal of the National Cancer Institute 2010, 102, 1478–1488. [Google Scholar] [CrossRef] [PubMed]
  6. Arbyn, M.; Tommasino, M.; Depuydt, C.; Dillner, J. Are 20 human papillomavirus types causing cervical cancer? J. Pathol. 2014, 234, 431–435. [Google Scholar] [CrossRef] [PubMed]
  7. Cooper, D.B.; Carugno, J.; Dunton, C.J.; Menefee, G.W. Cold Knife Conization of the Cervix; StatPearls [Internet]; StatPearls Publishing: Treasure Island, FL, USA, January 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK441845/ (accessed on 26 January 2024).
  8. Norwegian Directorate of Health. 7.4. Oppfølging og kontroller [7.4 Follow-up and controls]. Gynecological cancer Action Program (updated 18 January 2023). Available online: https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft--handlingsprogram/premaligne-lidelser-i-cervix-uteri/oppfolging-og-kontroller (accessed on 4 February 2024).
  9. Engesæter, B.; Hverven, S.K.; Skare, G.B.; Tropé, A. Årsrapport 2022: Screeningaktivitet og resultater fra Livmorhalsprogrammet [Annual Report 2022: Screening activity and results from the Cervical Screening Program]. Institute of Population-Based Cancer Research: Oslo, Norway, August 2023; p. 29. Available online: https://www.kreftregisteret.no/globalassets/livmorhalsprogrammet/rapporter/arsrapport-lp/arsrapportlp2022.pdf.
  10. Gatta, L.A.; Kuller, J.A.; Rhee, E.H.J. Pregnancy Outcomes Following Cervical Conization or Loop Electrosurgical Excision Procedures. Obstet. Gynecol. Surv. 2017, 72, 494–499. [Google Scholar] [CrossRef] [PubMed]
  11. Jin, G.; LanLan, Z.; Li, C.; Dan, Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch. Gynecol. Obstet. 2014, 289, 85–99. [Google Scholar] [CrossRef] [PubMed]
  12. Norwegian Institute of Public Health (NIPH). HPV-vaksine (Humant papillomavirus)—veileder for helsepersonell [HPV vaccine (Human Papillomavirus)—a guide for healthcare professionals]. Vaccination Guide for Healthcare Personnel (updated 21 March 2024). Available online: https://www.fhi.no/va/vaksinasjonsveilederen-for-helsepersonell/vaksiner-mot-de-enkelte-sykdommene/hpv-vaksinasjon-humant-papillomavir/?term= (accessed on 6 April 2024).
  13. Norwegian Institute of Public Health (NIPH). Vaccination for Human Papillomavirus (HPV) (Indicator 22). Indicators for Non-Communicable Diseases (NCD) (updated 5 December 2023). Available online: https://www.fhi.no/en/nc/Indicators-for-NCD/vaccine-and-screening/hpv-vaccine-indicator-22/?term= (accessed on 28 February 2024).
  14. Norwegian Cancer Society (NCS). HPV, HPV-vaksine og kreft [HPV, HPV vaccine and cancer]. (updated 14 March 2024). Available online: https://kreftforeningen.no/forebygging/hpv-og-kreft/ (accessed on 6 April 2024).
  15. Chen, M.; Li, C.; Cui, Q.; Zhou, C.; Chen, P.; Yao, S. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: A prospective observational study in China. Eur. J. Obstet. Gynecol. Reprod. Biol. 2023, 286, 10–15. [Google Scholar] [CrossRef] [PubMed]
  16. Casajuana-Pérez, A.; Ramírez-Mena, M.; Ruipérez-Pacheco, E.; Gil-Prados, I.; García-Santos, J.; Bellón-del Amo, M.; Hernández-Aguado, J.J.; de la Fuente-Valero, J.; Zapardiel, I.; Coronado-Martín, P.J. Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN 2-3: The VENUS Study. Vaccines 2022, 10, 288. [Google Scholar] [CrossRef] [PubMed]
  17. Gómez de la Rosa, A.G.; Quesada López-Fe, A.; Vilar Chesa, M.; Ferrer Machín, A.; Gimeno Gil, A.; Molina Bethancourt, A.; García Bello, M.Á.; Pérez-Méndez, L.I. Efficacy of Human Papillomavirus Vaccination 4 Years After Conization for High-Grade Cervical Neoplasia. J. Low. Genit. Tract. Dis. 2021, 25, 287–290. [Google Scholar] [CrossRef] [PubMed]
  18. Pieralli, A.; Bianchi, C.; Auzzi, N.; Fallani, M.G.; Bussani, C.; Fambrini, M.; Cariti, G.; Scarselli, G.; Petraglia, F.; Ghelardi, A. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease. Arch. Gynecol. Obstet. 2018, 298, 1205–1210. [Google Scholar] [CrossRef] [PubMed]
  19. Norwegian Directorate of Health. 7.5. HPV-vaksinering etter behandling for CIN2+ [7.5 HPV vaccination after treatment for CIN2+]. Gynecological cancer—Action program (updated 28 June 2021). Available online: https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft--handlingsprogram/premaligne-lidelser-i-cervix-uteri/hpv-vaksinering-etter-behandling-for-cin2 (accessed on 28 February 2024).
  20. Walboomers, J.M.; Jacobs, M.V.; Manos, M.M.; Bosch, F.X.; Kummer, J.A.; Shah, K.V.; Snijders, P.J.; Peto, J.; Meijer, C.J.; Muñoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12–19. [Google Scholar] [CrossRef]
  21. Liu, Z.; Liang, Q.; Ren, Y.; Guo, C.; Ge, X.; Wang, L.; Cheng, Q.; Luo, P.; Zhang, Y.; Han, X. Immunosenescence: molecular mechanisms and diseases. Signal. Transduct. Target. Ther. 2023, 8, 200. [Google Scholar] [CrossRef] [PubMed]
  22. Petráš, M.; Dvořák, V.; Lomozová, D.; Máčalík, R.; Neradová, S.; Dlouhý, P.; Malinová, J.; Rosina, J.; Lesná, I.K. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression. Sex. Transm. Infect. 2023, 99, 561–570. [Google Scholar] [CrossRef] [PubMed]
  23. Jentschke, M.; Kampers, J.; Becker, J.; Sibbertsen, P.; Hillemanns, P. Prophylactic HPV vaccination after conization: A systematic review and meta-analysis. Vaccine 2020, 38, 6402–6409. [Google Scholar] [CrossRef] [PubMed]
  24. Kreimer, A.R.; Guido, R.S.; Solomon, D.; Schiffman, M.; Wacholder, S.; Jeronimo, J.; Wheeler, C.M.; Castle, P.E. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 908–914. [Google Scholar] [CrossRef] [PubMed]
Preprints 103354 g001
Figure 1. Flow-chart of the inclusion process of treated women in the study.
Figure 1. Flow-chart of the inclusion process of treated women in the study.
Preprints 103354 g001
Table 1. Women treated with conization included in the study segmented by age. Each age bracket is divided into categories based on HPV-test results at the six-month follow-up and how many in each bracket received at least one dose of an HPV-vaccine. Percentage of HPV-positive women and vaccinated women is also calculated.
Table 1. Women treated with conization included in the study segmented by age. Each age bracket is divided into categories based on HPV-test results at the six-month follow-up and how many in each bracket received at least one dose of an HPV-vaccine. Percentage of HPV-positive women and vaccinated women is also calculated.
Age group HPV –
(n = 166)		 HPV + (%)
(n = 77, 31.7%)		 Total
(n = 243)		 Vaccinated (%)
(n = 77, 31.7%)
30 – 39 years 78 30 (27.8) 108 40 (37.0)
40 – 49 years 47 15 (24.2) 62 17 (27.4)
50 – 59 years 35 14 (28.6) 49 18 (36.7)
60 – 69 years 4 12 (75.0) 16 2 (12.5)
70 – 79 years 2 6 (75.0) 8 0 (0.0)
Table 2. Frequency table that compares the HPV vaccination status (no/yes) with the result of the HPV-test taken at the six-month follow-up (HPV–/HPV+).
Table 2. Frequency table that compares the HPV vaccination status (no/yes) with the result of the HPV-test taken at the six-month follow-up (HPV–/HPV+).
Vaccinated
(after conization)		 HPV –
(n = 166)		 HPV + (%)
(n = 77, 31.7%)		 Total
(n = 243)		 P-value
No 107 59 (35.5) 166 0.039
Yes 59 18 (23.4) 77
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated